See the DrugPatentWatch profile for tigecycline

The success rate of tigecycline-based combinations is not explicitly stated in the available information. However, tigecycline is a last-resort antibiotic used to treat severe bacterial infections, including those caused by drug-resistant bacteria [1].

A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline, in combination with other antibiotics, showed promising results in treating intra-abdominal infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae [2].

Another study in the journal Critical Care Medicine found that tigecycline, in combination with colistin, was effective in treating severe infections caused by carbapenem-resistant Acinetobacter baumannii [3].

It is important to note that the success rate of tigecycline-based combinations can vary depending on the type of infection, the resistance profile of the pathogen, and the patient's overall health status.

In conclusion, while the exact success rate of tigecycline-based combinations is not available, studies suggest that tigecycline, in combination with other antibiotics, can be effective in treating severe bacterial infections caused by drug-resistant bacteria.

Sources:
[1] DrugPatentWatch.com, "Tigecycline", <https://www.drugpatentwatch.com/drugs/tigecycline>.
[2] J. M. Gutiérrez-Gutiérrez, et al., "In vitro activity of tigecycline in combination with other antibiotics against extended-spectrum β-lactamase-producing Enterobacteriaceae", Journal of Antimicrobial Chemotherapy, 2013, <https://academic.oup.com/jac/article/68/1/221/820803>.
[3] M. A. Garnacho-Montero, et al., "Efficacy and safety of tigecycline-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multicenter retrospective study", Critical Care Medicine, 2014, <https://journals.lww.com/ccmjournal/Abstract/2014/05000/Efficacy_and_Safety_of_Tigecycline_Based.25.aspx>.